安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung . . .
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but
- Frontiers | ROS1-positive non-small cell lung cancer: from . . .
Abstract ROS1 rearrangements define a distinct, targetable subset of non–small cell lung cancer (NSCLC), representing ~2% of non-squamous cases and frequently presenting with metastatic disease and CNS involvement Multiple ROS1 tyrosine kinase inhibitors (TKIs)—from crizotinib to newer agents such as entrectinib, lorlatinib, repotrectinib, taletrectinib, and the highly selective
- Evolving Therapeutic Landscape of ROS1-Positive Non-Small . . .
ROS1 gene rearrangements define a distinct molecular subtype of non-small cell lung cancer (NSCLC), occurring in approximately 2% of cases and frequently associated with younger age, non-smoker status, and a high incidence of brain metastases The discovery of ROS1 as an oncogenic driver has led to the development of targeted tyrosine kinase inhibitors (TKIs) Crizotinib first demonstrated
- Nuvalent Announces FDA Acceptance of New Drug Application for . . .
Zidesamtinib has received breakthrough therapy designation for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ROS1 tyrosine kinase inhibitors and orphan drug designation for ROS1-positive NSCLC
- Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs
Several ROS1 tyrosine kinase inhibitors (TKIs) have been explored as first-line therapies for patients with advanced <i>ROS1< i> fusion–positive non–small cell lung cancers Only 3 TKIs (crizotinib, entrectinib, and repotrectinib) are currently approved by the U S Food and Drug Administration Repotrectinib is a preferred choice because of its relative efficacy, central nervous system
- Entrectinib in ROS1-positive advanced non-small cell lung . . .
We present efficacy and safety data from Cohort D of BFAST, an evaluation of entrectinib in treatment-naive patients with ROS1-positive NSCLC identified using NGS testing in liquid biopsies alone
- Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST
Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) We report integrated efficacy and safety from registrational taletrectinib studies in ROS1 + non–small cell lung cancer
- New treatment for ROS1+ non-small cell lung cancer
The change in the gene can cause uncontrolled cell growth and cancer The ROS1 gene is altered in about 1-2% of patients with lung cancer, usually NSCLC of the adenocarcinoma type Patients who are ROS1+ tend to be younger than the average patient with lung cancer and have little or no smoking history
|
|
|